By analysis of the clinical influence of PIK3R1 and AKT on AML with GEPIA, we discovered that the expression levels of PIK3R1 (also named PI3Kp85) and AKT3 were significantly higher in AML patients (N = 173) than in healthy people (N = 70) (Fig. S1A). This evidence concerns the gene PIK3R1 and acute myeloid leukemia.